Intellectual Property India Publishes Patent Application for 'RNAI Agents For Inhibiting Expression Of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, And Methods Of Use' Filed by Arrowhead Pharmaceuticals, Inc.

MUMBAI, India, May 30 -- Intellectual Property India has published a patent application (202517046030 A) filed by Arrowhead Pharmaceuticals, Inc., Pasadena, U.S.A., on May 13, for 'rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical compositions thereof, and methods of use.'

Inventor(s) include Carlson, Jeffrey; Wang, Yichen; Pei, Tao; Hamilton, James, C.; and Moradi, Hamid.

The application for the patent was published on May 30, under issue no. 22/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceu...